OliX Pharmaceuticals,Inc (226950.KQ)
KRW 18430.0
(-6.07%)
KRW 18430.0
(-6.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -19.1 Billion KRW | 2.02% |
| 2022 | -19.49 Billion KRW | 34.39% |
| 2021 | -29.71 Billion KRW | -53.29% |
| 2020 | -19.38 Billion KRW | -35.06% |
| 2019 | -14.35 Billion KRW | -85.39% |
| 2018 | -7.74 Billion KRW | -49.92% |
| 2017 | -5.16 Billion KRW | -41.26% |
| 2016 | -3.65 Billion KRW | -22.61% |
| 2015 | -2.98 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.4 Billion KRW | -363.08% |
| 2024 Q2 | -9.58 Billion KRW | -14.04% |
| 2023 Q1 | -8.5 Billion KRW | -228.66% |
| 2023 FY | -19.1 Billion KRW | 2.02% |
| 2023 Q3 | -4.92 Billion KRW | 44.44% |
| 2023 Q2 | -8.86 Billion KRW | -4.27% |
| 2023 Q4 | 3.19 Billion KRW | 164.85% |
| 2022 Q3 | -6.56 Billion KRW | 23.25% |
| 2022 Q1 | -9.03 Billion KRW | -25.31% |
| 2022 FY | -19.49 Billion KRW | 34.39% |
| 2022 Q4 | 6.6 Billion KRW | 200.62% |
| 2022 Q2 | -8.55 Billion KRW | 5.29% |
| 2021 Q1 | -8.26 Billion KRW | -7.84% |
| 2021 FY | -29.71 Billion KRW | -53.29% |
| 2021 Q4 | -7.21 Billion KRW | 21.41% |
| 2021 Q2 | -5.06 Billion KRW | 38.65% |
| 2021 Q3 | -9.17 Billion KRW | -81.09% |
| 2020 Q3 | -4.19 Billion KRW | 9.36% |
| 2020 Q2 | -4.62 Billion KRW | -59.39% |
| 2020 Q1 | -2.9 Billion KRW | 43.58% |
| 2020 Q4 | -7.65 Billion KRW | -82.61% |
| 2020 FY | -19.38 Billion KRW | -35.06% |
| 2019 Q2 | -3.36 Billion KRW | -41.99% |
| 2019 Q1 | -2.37 Billion KRW | -34.18% |
| 2019 Q3 | -3.46 Billion KRW | -3.08% |
| 2019 Q4 | -5.14 Billion KRW | -48.31% |
| 2019 FY | -14.35 Billion KRW | -85.39% |
| 2018 Q4 | -1.76 Billion KRW | 6.77% |
| 2018 FY | -7.74 Billion KRW | -49.92% |
| 2018 Q3 | -1.89 Billion KRW | 11.35% |
| 2018 Q2 | -2.13 Billion KRW | -10.05% |
| 2018 Q1 | -1.94 Billion KRW | 0.0% |
| 2017 FY | -5.16 Billion KRW | -41.26% |
| 2016 FY | -3.65 Billion KRW | -22.61% |
| 2015 FY | -2.98 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 89.898% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -97.018% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 508.964% |
| Bioneer Corporation | -10.58 Billion KRW | -80.425% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -572.394% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 427.084% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 60.956% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 70.195% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -126.558% |
| Medy-Tox Inc. | 9.75 Billion KRW | 295.812% |
| Peptron, Inc. | -15.92 Billion KRW | -19.971% |
| Amicogen, Inc. | -23.28 Billion KRW | 17.979% |
| Genexine, Inc. | -66.87 Billion KRW | 71.436% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -729.73% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 74.083% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -466.519% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 124.953% |
| SillaJen, Inc. | -20.36 Billion KRW | 6.223% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 236.774% |
| Genomictree Inc. | -8.75 Billion KRW | -118.155% |
| MedPacto, Inc. | -35.32 Billion KRW | 45.926% |
| D&D Pharmatech | 3.93 Billion KRW | 585.578% |
| EASY BIO,Inc. | 15.54 Billion KRW | 222.89% |
| GI Innovation, Inc. | -55.49 Billion KRW | 65.58% |